Incidence and survival of retinoblastoma in the Netherlands: a register based study 1862–1995

Annette C Moll, D Joop Kuik, Lex M Bouter, Willem Den Otter, P Dick Bezemer, Jan Willem Koten, Saskia M Imhof, Bertus P Kuyl, Karel E W P Tan

Abstract

Aim — The aim of this study was to determine the (time trends in) incidence and survival of hereditary (familial and sporadic) and non-hereditary retinoblastoma for male and female patients born in the Netherlands between 1862 and 1995.

Method — The national retinoblastoma register was updated and now consists of 955 patients. The missing dates of death were obtained from the municipal registers and the Central Bureau of Genealogy in The Hague. Mortality was compared with the Dutch vital statistics.

Results — From 1862 to 1995 no significant differences in incidence for retinoblastoma were found in the hereditary subgroups. Further, no significant differences between males and females were found, both overall and in the hereditary subgroups. The average incidence of retinoblastoma increased until 1944, probably due to incompleteness of the register, and stabilised after 1945 (1 per 17 000 live births). From 1990 to 1995 the standardised mortality ratio increased for hereditary retinoblastoma patients from 2.9 to 9.0 and decreased for non-hereditary retinoblastoma patients from 1.9 to 1.0.

Conclusion — Although survival for retinoblastoma was significantly better after 1945 than before, in comparison with the Dutch population the mortality between 1900 and 1990 increased for the hereditary and decreased for the non-hereditary retinoblastoma patients.

(Br J Ophthalmol 1997;81:559–562)

Retinoblastoma is a rare paediatric eye tumour which occurs in a hereditary and a non-hereditary form. All bilateral (familial or sporadic) and the familial unilateral cases can be considered to be hereditary (30%-40% of the cases).1 In familial cases the patient inherits the retinoblastoma mutation from a carrier parent and in sporadic bilateral cases from a healthy parent in whom a new germline mutation has occurred.

The incidence of retinoblastoma reported in the literature ranges from 1:10 000 in South Africa to 1:34 000 in the Netherlands (Table 1).1,2,3 These extreme values come from hospital populations and are based on very crude estimations and are therefore probably inaccurate.1 During the past years it has often been discussed whether there has been any change in the incidence of this malignant disease.2,3 The survival rate of retinoblastoma improved in the last century,4 mostly because of Wardrop’s recommendation to enucleate a retinoblastoma eye.5 As a consequence, hereditary retinoblastoma patients were able to have offspring and this presumably led to a gradual increase in the incidence of hereditary retinoblastoma in the population.

Furthermore, there is still a discussion in the literature regarding the sex predominance of retinoblastoma patients. Pendergrass and Davis7 found no difference in the incidence of retinoblastoma between males and females. Naumova and Sapienza8 found a significant overrepresentation of males among bilateral sporadic cases.

Neel10 and Vogel1 discussed a possible viral aetiology of retinoblastoma. A seasonal variation in births of children with non-hereditary retinoblastoma would suggest that the disease is possibly influenced by certain environmental agents such as viral infection.

The National Retinoblastoma Register of the Netherlands offers the unique opportunity to analyse the above mentioned controversies in the literature. Therefore, the purposes of this study were to determine for hereditary (sporadic and familial) and non-hereditary retinoblastoma patients: (1) the (time trends in) incidence, (2) the difference in incidence between males and females, (3) the difference in incidence between different months, (4) time trends in survival, (5) the difference in survival between male and female patients.

Methods

The National Retinoblastoma Register of the Netherlands28 29 was used in the updated version.30 It can be regarded as virtually complete for patients born from 1945 to date.17 We gathered the dates of birth and death of the 955 registered Dutch retinoblastoma patients born from 1862 to 1995. If possible, missing dates of death of patients were obtained with the help of the municipal registers and the Central Bureau of Genealogy in The Hague.

Retinoblastoma was regarded to be hereditary if at least one of the following criteria was met: bilateral retinoblastoma, family history for retinoblastoma (then the parent would be carrier of the defect in the retinoblastoma gene), or a defect in the retinoblastoma gene was found in chromosomal/DNA analysis of the patient. Sporadic hereditary retinoblastoma patients are the first cases known in a family. Some sporadic unilateral retinoblastoma pa-
### Table 1  Incidence figures of retinoblastoma cited in the literature

<table>
<thead>
<tr>
<th>Population</th>
<th>Time period</th>
<th>No of cases</th>
<th>Incidence*</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td>1965–75</td>
<td>80</td>
<td>1:10 000</td>
<td>Freedman and Goldberg, 1976&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
<tr>
<td>Malawi</td>
<td>1975</td>
<td>20</td>
<td>1:10 000</td>
<td>BenEfraim and Chirambo, 1976&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
<tr>
<td>America</td>
<td>1960–65</td>
<td>59</td>
<td>1:18 000</td>
<td>Devesa, 1975&lt;sup&gt;7&lt;/sup&gt;</td>
</tr>
<tr>
<td>Michigan, USA</td>
<td>1960–65</td>
<td>49</td>
<td>1:20 000</td>
<td>Falls and Neel, 1951&lt;sup&gt;8&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ohio, USA</td>
<td>1965–70</td>
<td>126</td>
<td>1:24 000</td>
<td>Macklin, 1961&lt;sup&gt;9&lt;/sup&gt;</td>
</tr>
<tr>
<td>USA</td>
<td>1974–75</td>
<td>70</td>
<td>1:18 000</td>
<td>Pendergrass and Davis, 1980&lt;sup&gt;10&lt;/sup&gt;</td>
</tr>
<tr>
<td>Asia</td>
<td>1940–80</td>
<td>126</td>
<td>1:24 000</td>
<td>Matsuoka and Ogyu, 1959&lt;sup&gt;11&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hokkaido, Japan</td>
<td>1940–80</td>
<td>69</td>
<td>1:24 000</td>
<td>Takanaka et al, 1991&lt;sup&gt;12&lt;/sup&gt;</td>
</tr>
<tr>
<td>Nagasaki, Japan</td>
<td>1940–80</td>
<td>60</td>
<td>1:24 000</td>
<td>O'Day et al, 1977&lt;sup&gt;13&lt;/sup&gt;</td>
</tr>
<tr>
<td>Australia, New Zealand</td>
<td>1940–80</td>
<td>80</td>
<td>1:17 000</td>
<td>Rickenberg et al, 1982&lt;sup&gt;14&lt;/sup&gt;</td>
</tr>
<tr>
<td>New Zealand</td>
<td>1948–77</td>
<td>100</td>
<td>1:18 000</td>
<td>Macklin, 1961&lt;sup&gt;9&lt;/sup&gt;</td>
</tr>
<tr>
<td>Europe</td>
<td>1928–57</td>
<td>180</td>
<td>1:19 000</td>
<td>Bech and Jensen, 1961&lt;sup&gt;15&lt;/sup&gt;</td>
</tr>
<tr>
<td>Denmark</td>
<td>1950–64</td>
<td>160</td>
<td>1:16 000</td>
<td>Taitkanen and Tuovinen, 1971&lt;sup&gt;16&lt;/sup&gt;</td>
</tr>
<tr>
<td>Finland</td>
<td>1951–60</td>
<td>295</td>
<td>1:28 000</td>
<td>Briard-Guillemon et al, 1974&lt;sup&gt;17&lt;/sup&gt;</td>
</tr>
<tr>
<td>France</td>
<td>1934–51</td>
<td>48</td>
<td>1:29 000</td>
<td>Vogel, 1979&lt;sup&gt;18&lt;/sup&gt;</td>
</tr>
<tr>
<td>Sweden</td>
<td>1940–80</td>
<td>88</td>
<td>1:18 000</td>
<td>Kock and Naeser, 1973&lt;sup&gt;19&lt;/sup&gt;</td>
</tr>
<tr>
<td>Norway</td>
<td>1950–70</td>
<td>75</td>
<td>1:17 000</td>
<td>Hørven, 1973&lt;sup&gt;20&lt;/sup&gt;</td>
</tr>
<tr>
<td>Middle East</td>
<td>1950–70</td>
<td>88</td>
<td>1:18 000</td>
<td>Kock and Naeser, 1973&lt;sup&gt;19&lt;/sup&gt;</td>
</tr>
<tr>
<td>Riyadh, Saudi Arabia</td>
<td>1962–6</td>
<td>22</td>
<td>1:12 000</td>
<td>Al-Idrissi et al, 1991&lt;sup&gt;11&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

*Incidence in number of retinoblastoma patients per live births.

### Results

#### HEREDITY

Sex and heredity of the retinoblastoma patients are shown in Table 2. Forty nine of the 350 hereditary retinoblastoma patients (14%) had the unilateral form; 320 of the 635 unilateral tumours were sited in the right eye and 296 in the left eye; in 19 unilateral cases the location of the tumour was unknown. The retinoblastoma subcohort 1945–94 has nearly the same composition as the total cohort (data not shown).

**INCIDENCE BY SEX**

In the period 1862–1995, no significant difference was found in incidence for retinoblastoma between males and females in the retinoblastoma subgroups (sporadic hereditary, familial hereditary, and non-hereditary). Furthermore, our investigation did not reveal any significant difference between the male/female ratio in various retinoblastoma subgroups and the Dutch population. Moreover, in the subcohort 1945–94 no significant difference in male/female ratio was found between the different retinoblastoma subgroups, or compared with the Dutch population (data no shown).

### TIME TRENDS IN INCIDENCE

Figure 1 shows the number of retinoblastoma patients per 100 000 live births in 5 year cohorts in the Netherlands. The incidence of retinoblastoma increased significantly from 1862 to 1945. After 1945 there was no evidence of an increase in the total incidence of retinoblastoma, nor was there any significant change in incidence in the retinoblastoma subgroups (sporadic hereditary, familial hereditary, and non-hereditary retinoblastoma; data not shown). The average incidence of retinoblastoma after 1945 was 1:17 000 (95% CI; 1:15 500–1:18 500) (5.8 per 100 000) live births (range 13 000–25 000).

### Table 2  Sex and heredity of patients in the National Retinoblastoma Register of the Netherlands from 1862 to 1995

<table>
<thead>
<tr>
<th>Group</th>
<th>Male (%)</th>
<th>Female (%)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-hereditary</td>
<td>318 (54.3)</td>
<td>268 (45.7)</td>
<td>586</td>
</tr>
<tr>
<td>Sporadic hereditary</td>
<td>130 (52.2)</td>
<td>119 (47.8)</td>
<td>249*</td>
</tr>
<tr>
<td>Familial hereditary</td>
<td>47 (46.5)</td>
<td>54 (53.5)</td>
<td>101†</td>
</tr>
<tr>
<td>Unknown</td>
<td>8</td>
<td>11</td>
<td>19</td>
</tr>
<tr>
<td>Total</td>
<td>503 (52.7)</td>
<td>452 (47.3)</td>
<td>955</td>
</tr>
</tbody>
</table>

*Including 29 unilateral patients.
†Including 20 unilateral patients.
Incidence and survival of retinoblastoma in the Netherlands

The incidence is expressed in number of retinoblastoma patients per 100 000 live births in the Netherlands in the same period (irrespective of the moment of diagnosis).

Figure 1 Incidence of retinoblastoma in the Netherlands in 5 year cohorts from 1862 to 1994. The incidence is expressed in number of retinoblastoma patients per 100 000 live births in the Netherlands in the same period (irrespective of the moment of diagnosis).

Table 3 Cumulative survival for the subcohorts of retinoblastoma patients: 1945–94

<table>
<thead>
<tr>
<th>Group</th>
<th>Survival* until age 5</th>
<th>Survival* until age 35</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-hereditary</td>
<td>395</td>
<td>91.8%</td>
</tr>
<tr>
<td>Hereditary</td>
<td>242</td>
<td>87.2%</td>
</tr>
<tr>
<td>Sporadic hereditary</td>
<td>164</td>
<td>87.4%</td>
</tr>
<tr>
<td>Familial hereditary</td>
<td>78</td>
<td>86.8%</td>
</tr>
<tr>
<td>Female</td>
<td>300</td>
<td>91.6%</td>
</tr>
<tr>
<td>Male</td>
<td>337</td>
<td>88.7%</td>
</tr>
<tr>
<td>All</td>
<td>637</td>
<td>90.1%</td>
</tr>
</tbody>
</table>

*Survival per number of liveborn retinoblastoma patients.

INCIDENCE PER MONTH

The distribution of the retinoblastoma subgroups does not show significant differences over the 12 months of the year in comparison with the Dutch population. There appears to be a slight, but not significant excess of retinoblastoma affected newborns from December to May (data not shown).

SURVIVAL

In all, 287 of the 955 patients born between 1862 and 1995 had died; 640 patients were still alive and 28 patients could not traced for follow up. Five hundred and thirty eight of the 955 patients born between 1862 and 1995 had died; 640 patients were still alive and 28 patients could not traced for follow up. Five hundred and thirty eight patients had died; 640 patients were still alive; 99 patients had died and eight patients could not be traced for follow up. Cumulative survival at 5 and 35 years of age for the different retinoblastoma subgroups is shown in Table 3. There was a significant difference in cumulative survival between hereditary and non-hereditary retinoblastoma (p<0.005). The difference in survival between sporadic hereditary and familial hereditary survival was not significant. The difference in survival between male and female retinoblastoma patients was also not statistically significant.

The survival at 5 years (p<0.01) and 35 years (p<0.01) of age was significantly better for patients born after 1945 than for patients born before 1945. SMRs for the period 1898–1995 are given in Table 4. No trend in the SMR could be found for the total group. However, for the hereditary patients the SMR increased significantly (p=0.007), while for the non-hereditary patients a significant decrease trend was found (p=0.017).

Table 4 Standardised mortality ratio (SMR) for retinoblastoma patients

<table>
<thead>
<tr>
<th>Cohort</th>
<th>SMR (95% CI)</th>
<th>SMR (95% CI)</th>
<th>SMR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All RB</td>
<td>1998–1907</td>
<td>3.1 (2.1–4.7)</td>
<td>9.0 (5.5–14.4)</td>
</tr>
<tr>
<td>Hereditary</td>
<td>1998–1907</td>
<td>3.1 (2.1–4.7)</td>
<td>9.0 (5.5–14.4)</td>
</tr>
<tr>
<td>Non-hereditary</td>
<td>1998–1907</td>
<td>3.1 (2.1–4.7)</td>
<td>9.0 (5.5–14.4)</td>
</tr>
</tbody>
</table>

RB = retinoblastoma.

Discussion

HEREDITY

The percentage of hereditary and non-hereditary retinoblastoma (61.4% and 36.6%, respectively) was similar to the percentage published by Vogel. In addition, he found that 10%–12% of the unilateral sporadic cases were in fact new germline mutants; we found a nearly similar percentage of 14.0.

INCIDENCE BY SEX

Several studies showed no sex differences in the incidence of retinoblastoma.5 11 35 Nau- mova and Sapienza26 made an extensive compilation of the literature regarding sex and laterality of proved sporadic cases and found a significant overrepresentation of males among bilateral sporadic cases. For unilateral retinoblastoma they could not find such a difference. We could not confirm their first mentioned findings.

TIME TRENDS IN INCIDENCE

As discussed by Vogel, studies covering more recent periods tend to give higher values of incidence of retinoblastoma. The most obvious explanation is a more complete ascertainment in the more recent studies. This can also explain the increasing incidence we found in the period 1862–1944. It seems that especially in the period 1862–1900 the tumour was often not recognised and/or registered. Vogel did not exclude that there has been a true increase in incidence of retinoblastoma. However, the incidence in the period 1945–94 did not change significantly in our study. Perhaps, in this period the tumour was diagnosed correctly and the register was really complete.

INCIDENCE PER MONTH

Earlier reports1 5 11 30 failed to show clustering of sporadic hereditary or non-hereditary retinoblastoma in specific months. Our data revealed fluctuations to some extent by month of birth, but this was not statistically significant.

SURVIVAL

In 1809, Wardrop advocated enucleation of a retinoblastoma containing eye as a lifesaving measure. It is the general opinion that early enucleation contributed to a better survival. However, new treatment modalities (irradia-
tion or coagulation) were developed to save life and preserve vision. Bishop and Madsen reported an increase in the survival of retinoblastoma of 5% in 1869 to 81% in 1967. This study also showed an increasing survival. It should be stressed also that from 1900 the survival in the general population increased dramatically. Taking this into account, it is clear from the trend analysis of the SMR that survival for the hereditary group could not follow the improvement in the general population.

The risk of death is significantly higher for a retinoblastoma patient than for an average member of the Dutch population, as all SMRs are larger than 1. In other words, the improved diagnostic technique and improved retinoblastoma treatment did not result in the same increase in survival for the hereditary group. The risk of death is significantly higher for a patient with hereditary retinoblastoma than that of non-hereditary patients, because non-hereditary patients are more often irradiated than that of non-hereditary patients, because non-hereditary patients are mostly enucleated. Der Kinderen et al. have shown that irradiation therapy is an extra risk factor for second primary tumours in hereditary retinoblastoma patients. This will lead to death in many cases. On the other hand no second primary tumours were induced by irradiation of non-hereditary retinoblastoma patients; consequently, non-hereditary retinoblastoma patients will be cured and survival will be improved.

This study was supported by grants from the Haak-Bastaans-Kuneman-stichting.

30 Moll AC, Imhof SM, Koten JW, Bezemer PD, Bezemer FA, Den Otter W. Parental age in sporadic hereditary retinoblastoma patients; consequently, non-hereditary retinoblastoma patients will be cured and survival will be improved.
Incidence and survival of retinoblastoma in the Netherlands: a register based study 1862–1995

Annette C Moll, D Joop Kuik, Lex M Bouter, Willem Den Otter, P Dick Bezemer, Jan Willem Koten, Saskia M Imhof, Bertus P Kuyt and Karel E W P Tan

Br J Ophthalmol 1997 81: 559-562
doi: 10.1136/bjo.81.7.559

Updated information and services can be found at:
http://bjo.bmj.com/content/81/7/559

These include:

References
This article cites 25 articles, 2 of which you can access for free at:
http://bjo.bmj.com/content/81/7/559#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Epidemiology (1068)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/